Hematologic Cancers: Continued Treatment with Tafasitamab

We are providing ongoing treatment for patients with blood cancers who have previously received Tafasitamab. This study focuses on evaluating the safety of continued use of this medication.

Confirmation phase (III)Post-Trial Drug AccessNo PlaceboPartially RemoteStandard MedicinesInjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Minjuvi
Minjuvi is a cancer medicine used to treat certain types of non-Hodgkin lymphoma in adults.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Tafasitamab
Tafasitamab is a targeted antibody that helps the immune system attack B-cell cancers, particularly some types of non-Hodgkin lymphoma.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz
2nd Dept. of Internal Medicine and Haematology
Győr, Hungary
Azienda Unita Sanitaria Locale Della Romagna
Oncoematologia
Ravenna, Italy
Azienda Ospedaliera S Maria Di Terni
Oncohematology
Terni, Italy
Sponsor: Incyte Corp.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.